Tempus
Tempus Submits PMA Application for Tumor Profiling Assay to FDA
The firm has submitted companion diagnostic and tumor profiling, and MSI status claims using DNA from FFPE tumor tissue and matched normal specimens.
In Brief This Week: Foundation Medicine, Myriad Genetics, Immunovia, Biocept, and More
News items for the in vitro diagnostics industry for the week of June 28, 2021.
In Brief This Week: Quidel, Ortho Clinical Diagnostics, Hologic, Guardant Health, and More
News items for the in vitro diagnostics industry for the week of Feb. 1, 2021.
Tempus, A2 Biotherapeutics Partner to Develop CDx for Therapy Targeting Loss of Heterozygosity
Using its xT sequencing platform, Tempus will create a companion test to identify patients eligible for treatment with A2's cell-based LOH-targeted therapy.
JP Morgan Healthcare Conference 2021, Day One: Roche, Guardant, Hologic, Thermo Fisher, and More
Among firms presenting on the first day, Roche provided insights into its COVID-19 testing business, and Guardant said it plans to launch a comprehensive tissue sequencing assay.Â